PSYCHEMEDICS CORP (PMD)
US7443752057 - Common Stock
PMD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 118 industry peers in the Health Care Providers & Services industry. PMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PMD does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year PMD has reported negative net income.
In the past year PMD has reported a negative cash flow from operations.
PMD had negative earnings in 4 of the past 5 years.
In multiple years PMD reported negative operating cash flow during the last 5 years.
1.2 Ratios
PMD has a worse Return On Assets (-33.71%) than 82.05% of its industry peers.
PMD's Return On Equity of -62.28% is on the low side compared to the rest of the industry. PMD is outperformed by 70.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.71% | ||
| ROE | -62.28% | ||
| ROIC | N/A |
ROA(3y)-14.19%
ROA(5y)-10.61%
ROE(3y)-25.92%
ROE(5y)-19.89%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of PMD (38.09%) is better than 66.67% of its industry peers.
In the last couple of years the Gross Margin of PMD has declined.
The Profit Margin and Operating Margin are not available for PMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y18.48%
GM growth 5Y-4.66%
2. Health
2.1 Basic Checks
PMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PMD has more shares outstanding
Compared to 5 years ago, PMD has more shares outstanding
Compared to 1 year ago, PMD has an improved debt to assets ratio.
2.2 Solvency
PMD has an Altman-Z score of 0.87. This is a bad value and indicates that PMD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.87, PMD perfoms like the industry average, outperforming 42.73% of the companies in the same industry.
PMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.87 |
ROIC/WACCN/A
WACC8.95%
2.3 Liquidity
A Current Ratio of 1.45 indicates that PMD should not have too much problems paying its short term obligations.
The Current ratio of PMD (1.45) is comparable to the rest of the industry.
PMD has a Quick Ratio of 1.45. This is a normal value and indicates that PMD is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of PMD (1.45) is better than 62.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.45 |
3. Growth
3.1 Past
The earnings per share for PMD have decreased strongly by -280.40% in the last year.
Looking at the last year, PMD shows a very negative growth in Revenue. The Revenue has decreased by -12.45% in the last year.
Measured over the past years, PMD shows a very negative growth in Revenue. The Revenue has been decreasing by -12.33% on average per year.
EPS 1Y (TTM)-280.4%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-35.63%
Revenue 1Y (TTM)-12.45%
Revenue growth 3Y1.14%
Revenue growth 5Y-12.33%
Revenue growth Q2Q-12.32%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PMD. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 10.62%, PMD is a good candidate for dividend investing.
PMD's Dividend Yield is rather good when compared to the industry average which is at 2.74. PMD pays more dividend than 99.15% of the companies in the same industry.
PMD's Dividend Yield is rather good when compared to the S&P500 average which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 10.62% |
5.2 History
The dividend of PMD decreases each year by -27.43%.
PMD has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-27.43%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
The earnings of PMD are negative and hence is the payout ratio. PMD will probably not be able to sustain this dividend level.
DP-19.23%
EPS Next 2YN/A
EPS Next 3YN/A
PSYCHEMEDICS CORP
NASDAQ:PMD (5/7/2024, 3:12:48 PM)
2.53
-0.01 (-0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap14.70M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 10.62% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.71% | ||
| ROE | -62.28% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.09% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.45 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-280.4%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-12.45%
Revenue growth 3Y1.14%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y